MARKET

CRVO

CRVO

CervoMed
NASDAQ
7.90
-0.08
-1.00%
After Hours: 7.90 0 0.00% 16:10 12/31 EST
OPEN
7.97
PREV CLOSE
7.98
HIGH
8.03
LOW
7.67
VOLUME
68.09K
TURNOVER
--
52 WEEK HIGH
16.94
52 WEEK LOW
1.920
MARKET CAP
73.10M
P/E (TTM)
-2.7557
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRVO last week (1222-1226)?
Weekly Report · 12/29/2025 09:49
Weekly Report: what happened at CRVO last week (1215-1219)?
Weekly Report · 12/22/2025 09:49
Cantor Fitzgerald Initiates Coverage On CervoMed with Overweight Rating
Benzinga · 12/18/2025 13:02
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 12/18/2025 12:16
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
Benzinga · 12/18/2025 12:07
CervoMed initiated with an Overweight at Cantor Fitzgerald
TipRanks · 12/18/2025 11:40
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
TipRanks · 12/18/2025 11:35
Weekly Report: what happened at CRVO last week (1208-1212)?
Weekly Report · 12/15/2025 09:53
More
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Webull offers CervoMed Inc stock information, including NASDAQ: CRVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVO stock methods without spending real money on the virtual paper trading platform.